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Abstract

 astroparesis is defined as a delay in gastric emptying in the absence of mechanical obstruction in
G
the stomach. Gastroparesis has a number of causes, including postsurgical, secondary to medications,
postinfectious, idiopathic, and as a complication of diabetes mellitus, where it is underrecognized. The
cardinal symptoms of diabetic gastroparesis are nausea, early satiety, bloating, and vomiting. Diabetic
gastroparesis is more common in females and has a cumulative incidence of 5% in type 1 diabetes and
1% in type 2 diabetes. It is associated with a reduction in quality of life and exerts a significant burden on
health care resources. The pathophysiology of this disorder is incompletely understood. Diagnosis is made
based on typical symptoms associated with the demonstration of delayed gastric emptying in the absence
of gastric outlet obstruction. Gastric emptying scintigraphy is the gold standard for demonstrating delayed
gastric emptying, but other methods exist including breath testing and the wireless motility capsule. Diabetic
gastroparesis should be managed within a specialist multidisciplinary team, and general aspects involve
dietary manipulations/nutritional support, pharmacological therapy, and surgical/endoscopic interventions.
Specific pharmacological therapies include prokinetics and antiemetics, with several new medications in
the drug development pipeline. Surgical/endoscopic interventions include botulinum toxin injection into
the pylorus, gastric peroral endoscopic myotomy and gastric electrical stimulation. This article provides
a detailed review and summary of the epidemiology, pathophysiology, investigation, and management of
diabetic gastroparesis, and also gives an individual patient’s perspective of living with this disabling disorder.
(J Patient Cent Res Rev. 2019;148-157.)
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astroparesis is defined as a delay in gastric
emptying in the absence of mechanical
obstruction in the stomach.1,2 Causes of
gastroparesis can be postsurgical, secondary to
medications (eg, opioids, anticholinergics, tricyclic
antidepressants, beta-blockers, calcium channel
blockers), postinfectious, idiopathic, or a complication
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of diabetes mellitus. The differential diagnoses of
gastroparesis include cyclic vomiting syndrome and
cannabinoid-induced hyperemesis.3 The emergence of
gastrointestinal (GI) complications of diabetes mellitus
are a function of poor glycemic control rather than
the longevity of the diagnosis.4 The most common
complication is diabetic gastroparesis (DG) and is
often underrecognized.5 The cardinal symptoms of
DG are nausea, early satiety, vomiting, dyspepsia, and
bloating. DG is associated with impaired glycemic
control, marked psychological distress, and reduced
quality of life.6 This review paper provides a dual
perspective of DG: firstly, that of the health care
Review

professional, which will focus on the pathophysiology,
clinical evaluation, and treatment of DG, and secondly,
that of the patient, with regard to the experience of
living with DG.

EPIDEMIOLOGY OF GASTROPARESIS

Population-based epidemiological DG data is sparse
as the majority of studies are case series from single,
usually specialized, centers. In a community-based
study of DG in the United States, the cumulative
incidence was higher in type 1 diabetes mellitus (5%)
than type 2 diabetes mellitus (1%).7 Moreover, data
suggest that hospital admissions related to gastroparesis
have increased significantly between 1995 and 2004.8
The costs associated with inpatient management of
gastroparesis have increased, after adjustment for
inflation, from $13,350 per patient in 1997 to $34,585
per patient in 2013.9 There is a higher incidence in
females of 4:1 compared to males, and the disorder most
commonly presents between the ages of 30 and 40 years
in type 1 diabetes mellitus.10 In general, females report
more severe symptoms but have less hospital admissions
in comparison to males.11 While the absolute cause of
the gender differences is not completely understood,
possible explanations include the fact that males have
generally faster gastric emptying than females12 and,
in female rodent models, the effect of diabetes on the
enteric nervous system is higher.13,14

CONTROL OF GASTRIC EMPTYING

The regulation of gastric motility represents a complex
functional interplay between the vagus nerve, enteric
nervous system, interstitial cells of Cajal (ICC, which
act as pacemaker cells), and the smooth muscle of
the stomach.15 With respect to food ingestion, the
stomach can broadly be considered to consist of two
complementary parts, namely the proximal and distal
stomach. The proximal stomach, consisting of the
fundus, relaxes to accommodate the ingested food,
which in itself leads to further relaxation by activation
of mechanosensitive receptors via the vagus nerve.
Within the greater curve, at the junction between the
fundus and the body of the stomach, ICC generate
rhythmic slow-wave electrical activity, which induces
peristalsis that transitions food from the proximal to
the distal stomach, ie, the body and antrum. In the
distal stomach, antral contractions, against a closed
pylorus, serve to “grind” food into smaller particles.16
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Following this, the pylorus relaxes and opens and the
food is then ejected into the proximal small bowel
through an antroduodenal reflex. The rate of emptying
is highly regulated in order to optimize the delivery
of nutrients to ensure maximal absorption and is
modulated by a number of hormones, such as the
incretins and glucagon.17 These hormones slow the rate
of gastric emptying, thereby controlling postprandial
glycemia. The gastric emptying of liquids is more
rapid than solids (1–2 hours vs 3–4 hours), and those
nutrients with a higher calorific value are emptied more
slowly.18 These factors are schematically summarized
in Figure 1.

PATHOPHYSIOLOGY OF DIABETIC
GASTROPARESIS

While the exact pathophysiological mechanisms that
lead to DG are incompletely understood, a number
of factors have been implicated. These include vagus
nerve dysfunction, the effect of glycemic excursions,
diminution of expression neuronal nitric oxide
synthase with the myenteric plexus on the enteric
nervous system, disturbance of ICC networks, and
a proinflammatory state that results in excessive
oxidative stress.19,20

CLINICAL EVALUATION AND
INVESTIGATIONS

A careful and detailed history needs to be undertaken
to establish the presence of cardinal symptoms (nausea,
early satiety, vomiting, bloating), as the cornerstone
of diagnosis is clinical in nature.21 It is important to
establish the presence or absence of vomiting and
also to exclude the rumination syndrome, which
is characterized by effortless vomiting.22 It is also
important to seek a full detailed history regarding
the person’s diabetes to include the presence of
complications such as retinopathy or peripheral
sensorimotor neuropathy.
Physical examination should focus on looking for
stigmata of peripheral and autonomic neuropathy,
abdominal distension with the presence or absence of a
succussion splash being a useful clinical sign. Routine
biochemical, hematologic, and hormonal parameters
are useful. If DG is suspected, an upper GI endoscopy
should be undertaken to exclude mechanical gastric
outlet obstruction, the symptoms of which are virtually
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Figure 1. Gastric function in normal state (A) and in diabetic gastroparesis (B).

A number of coordinated neuronal and myenteric processes are needed for normal
coordinated gastric emptying. When these processes are disrupted at any level,
then delayed gastric emptying may occur and symptoms may ensue.
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identical. In the small proportion of patients who cannot
tolerate/are unfit to undergo an upper GI endoscopy, a
barium meal may be an alternative.
There are a number of techniques to measure gastric
emptying, though scintigraphy is considered to be the
gold standard.23,24 This is a noninvasive, quantitative
method that involves the patient consuming a test meal
consisting of 2 slices of bread with jam and 2 large eggs
inoculated with 99-technetium. Scintigraphy scanning
is performed at baseline and then after 30 minutes, 1
hour, 2 hours, and 4 hours postprandially.25 The 1-hour
scan is used to detect rapid gastric emptying, with a
retention of less than 30% being consistent with this.
The 2- and 4-hour scans are used to detect delayed
gastric emptying, defined as a retention >60% or
>10%, respectively.25 As an alternative to percentage
retention, gastric emptying time is sometimes reported.
A half-emptying time greater than 80 minutes
represents delayed gastric emptying.
The limitation of the test meal is that it is of small
calorific value and often fails to reproduce symptoms.

Alternative test meals such as the Nottingham test meal,
which consists of 400 mL liquid nutrient (0.75 kcal/
mL), an optional solid component (12 solid agar beads),
and recording of dyspeptic and filling sensations,
also are available but require further validation in
patient studies.26 Filling and dyspeptic sensations are
concomitantly recorded using a visual analogue scale.
Other methods of measuring gastric emptying include
the wireless motility capsule and breath testing (Figures
2 and 3). The wireless motility capsule consists of
an indigestible capsule, which detects luminal pH,
temperature, and pressure as it passes through the GI
tract, that wirelessly transmits high-frequency data to
an external receiver.27 Based on stereotypical changes
in pH and temperature, gastric emptying, small-bowel
transit time, colonic transit time, and whole-gut transit
time. The wireless motility capsule compares well to
scintigraphy and has robust normal values.28-30 The
breath testing utilizes a nonradioactive 13C isotope
bound to a digestible substance, most commonly
octanoic acid or spirulina. 13C octanoic acid or spirulina
is then mixed into an egg meal and ingested, where it

Figure 2. Standardized testing protocol for the wireless motility capsule and a typical trace demonstrating gastric
emptying time (GET), small-bowel transit time (SBTT), and colonic transit time (CTT), from which the whole-gut
transit time can be derived.
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DG is to restore and preserve the patient’s overall
nutritional status. Clearly, dietary modifications are an
important aspect of general diabetes management that
will in themselves improve glycemic control.

Figure 3. Schematic representation of the principles

underpinning 13C octanoic acid breath testing to derive
gastric emptying.

is absorbed from the small bowel and is subsequently
metabolized by the liver to 13C-CO2. It is then expelled
from the lungs and measured in exhaled breath. The
main advantages of these new technologies are that
they limit radiation exposure to the patient, although
their general availability at the current time is limited.

TREATMENT

DG is most effectively managed in the context
of a wider multidisciplinary team that includes
gastroenterologists, diabetologists, dieticians, and
surgeons. The treatment of DG should adopt a stepwise
approach that involves general aspects, dietary
manipulations/nutritional support, pharmacological
therapy, and surgical/endoscopic interventions.

Given the complexities of dietetic approaches to
diabetic patients, modifications should be undertaken
by a registered dietician with expertise in the area. A
detailed clinical history establishing the types and
consistencies of foods that are tolerated should be
sought. In addition, the effect of content, timing, and
size of meals and their relationship to symptoms should
be established. Changing the frequency, size, and
nutritional composition of meals can improve symptoms
and is the cornerstone of initial management of DG.32
Patients should be encouraged to eat more liquid-based
meals, given that liquids empty more rapidly than
solids. Similarly, lower residue and lower fiber intake
may be helpful. Lower fat/calorie-content meals also are
advised, as these are emptied more rapidly.33,34
Pharmacological Therapy
Current drug treatments in DG aim to promote gastric
emptying or reduce nausea/vomiting. Prokinetic agents
aim to accelerate the transit of food from the stomach to
the small bowel. It is surmised that prokinetics reduce
gastric dysrhythmias and improve antral contractility
and antroduodenal coordination.35

General Aspects
General approaches include optimization of glycemic
control, with correction of electrolyte imbalance if
needed. A review of concomitant medications needs to
be undertaken, as many classes of drug retard gastric
emptying, including opioids, anticholinergics, and
calcium channel blockers. When possible, such drugs
should be discontinued if possible or at least minimized.

Antidopaminergics:
Domperidone
and
metoclopramide are D2 receptor blockers that exert
their mechanism of action in the periphery and central
areas, respectively. They have both prokinetic and
antiemetic actions. While these drugs are generally well
tolerated, both have been associated with potentially
fatal cardiac arrhythmias through prolongation of QTc
interval.36 With domperidone, there are higher risks in
certain circumstances: use in those >60 years old, a
daily dose in excess of 30 mg, and use in those taking
other concomitant medications that prolong the QT
interval or inhibitors of CYP3A4. Domperidone is not
available in the United States.

Dietary Manipulation and Nutritional Support
Given the symptoms of DG, patients often limit their
oral intake, leading to dehydration, weight loss, and
macronutrient/mineral/vitamin deficiencies.31 The
overarching principle in the dietary management of

Given that metoclopramide crosses the blood brain
barrier, it can cause extrapyramidal side effects and,
rarely, irreversible tardive dyskinesia. Age 60 years and
older, female gender, concomitant neuroleptics, and
preexisting movement disorders confer a heightened
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risk of this complication.36 If physicians are considering
commencing this medication, fully informed consent
with a concomitant written contract needs to be executed.
In February 2009, the Food and Drug Administration
mandated a black box warning for metoclopramide,
due to risks of tardive dyskinesia, and advocated that
treatment periods should not exceed 3 months. Beyond
this, treatment can be continued in rare/exceptional
circumstances in which benefit outweighs risk.37
Serotoninergics: 5-HT4 receptor agonists increase
the release of acetylcholine from the efferent motor
neurons in the enteric nervous system, which enhances
contractions within the GI tract thereby accelerating
motility. However, safety concerns regarding cardiac
arrhythmias (cisapride) and ischemic colitis (tegaserod)
have limited their availability.38 Nevertheless, more
selective 5-HT4 receptor agonists, such as prucalopride,
may offer an alternative.39 A small study showed that
prucalopride increases the rate of gastric emptying,
though further studies are required to confirm this in
clinical populations.40
Antiemetics: In addition to the antidopaminergic agents,
5-HT3 antagonists, antimuscarinic anticholinergics,
H1 antagonists, and NK1 antagonists are established
antiemetics. Although these drugs improve nausea,
the utility is frequently limited by their anticholinergic
side effects that slow gastric motility.
Ghrelin Agonists: Ghrelin is a gastric peptide
that increases gastric activity in the postprandial
and interdigestive periods and improves appetite.
Relamorelin is a novel synthetic pentapeptide
amide that is a potent ghrelin-receptor agonist.41 In
comparison to endogenous ghrelin, it has increased
potency, plasma stability, and a longer circulating halflife. Phase II trial data, at a twice daily subcutaneous
dose of 10 mcg as compared to placebo, demonstrated
that relamorelin improves gastric emptying and reduces
vomiting episodes by 60%.42 Two large international
multicenter studies evaluating relamorelin in DG are
currently ongoing.
Invasive/Surgical Treatments
Endoscopic Therapies: A proportion of patients
representing the severe end of the spectrum may
need to be considered for escalation to nutritional
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support. Clinical factors that may trigger this include
unintentional loss of >10% of body weight over 6
months and refractory symptoms. In this context, a trial
of feeding distal to the pylorus with a nasojejunal tube
is of utility as a short-term measure in stabilizing and
ultimately improving nutritional status. If successful, it
may be followed by the placement of an endoscopically
or surgically placed jejunostomy or gastrostomy with
jejunal extension. Such enteral feeding strategies have
been demonstrated to improve symptoms, reduce
hospital admissions, and relieve symptoms.43 In a small
uncontrolled trial, venting gastrostomy was shown to
reduce symptoms and improve functioning.44
Intrapyloric injection of botulinum toxin, delivered
at endoscopy, has been investigated as a management
strategy in DG, albeit with unconvincing results.45 It
is postulated that the neurotoxin inhibits the release of
acetylcholine at the neuromuscular junction, causing
pyloric paralysis and allowing gastric contents to
empty more readily into the duodenum.46 The largest
uncontrolled retrospective study of 179 patients
(of which 81 had DG) reported an improvement in
symptoms and body weight in the 4 months after
intrapyloric botulinum toxin injection.47 However,
Friedenberg et al reported that intrapyloric injection
of botulinum toxin did not improve gastric emptying
or symptoms over placebo at 1 month in a cohort of
32 patients.48 Similarly, using a randomized crossover
design, Arts et al demonstrated that intrapyloric
injection of botulinum toxin was not superior to
placebo in improving either the rate of gastric emptying
or symptoms, although this study was performed in
those with idiopathic gastroparesis.49 Gastric peroral
endoscopic myotomy (G-POEM) has been studied
in DG and is associated with an improvement in
symptoms and gastric emptying to at least 6 months,
with an acceptable complication rate.50,51
Surgical Interventions: Laparoscopically performed
Heineke-Mikulicz pyloroplasty is considered to be an
effective treatment for DG.52 The technique involves
making a 5 cm full-thickness pyloromyotomy from
the antrum to the duodenum, which is subsequently
closed in a transverse fashion.53 In a prospective cohort
study of 177 patients, there was an improvement in
the cardinal symptoms of gastroparesis at 3 months,
and more than 75% had a normalization of gastric
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scintigraphy, and it is not clear how many patients had
DG. A small propensity-matched cohort study based
on 30 patients with gastroparesis (of which 5 had
DG) compared surgical laparoscopic pyloroplasty to
endoscopic G-POEM and demonstrated a reduction in
perioperative morbidity in the endoscopic group, with
similar functional outcomes.54
Patients with refractory DG can be offered implantable
gastric electrical stimulation (GES), although
availability varies between different health care
economies. GES involves the surgical implantation
of suturing of electrodes to the gastric antrum, which
are then subsequently attached to a stimulus generator
typically sited in a subcutaneous pocket in the left
upper quadrant (Figure 4). Although improvement in
symptoms is generally reported in open-label studies,
a recent meta-analysis that included randomized
placebo-controlled trials did not show any significant
group differences in global or cardinal symptoms after
GES, in the context of an overall complication rate of
1 in 10.55 Nevertheless, patients with the most severe
symptoms gained the largest therapeutic improvement.
However, when considering the marked difference
reported between open-label and placebo-controlled
studies, it does suggest that there is a significant
placebo response in what, by definition, is a group of
patients with severe symptoms. Thus, the development
of more objective and robust outcome measures that
go beyond subjective reporting of symptoms is needed.
In addition, the follow-up from the aforementioned
studies is generally short, and longer-term outcomes
in cohorts often display good improvement over time.

Figure 4. Surgical implantation of a gastric electrical
stimulator. Panel A demonstrates suturing of the
electrodes to the anterior wall of the antrum. Panel
B shows the connection of the electrodes to the
signal generator. Panel C depicts the insertion of the
stimulator into a subcutaneous pocket.

emptying.53 The overall morbidity rate was acceptable
at 6.8%, though 10% required further interventions
such as gastric electrical stimulator implantation. The
weakness of this study was that it included patients
whose gastric emptying was normal as measured by
154 JPCRR • Volume 6, Issue 2 • Spring 2019

It is our experience that patients with recalcitrant
symptoms do derive benefit from GES. Further work
needs to be undertaken to identify objective patient
factors that predict GES treatment response, such as
relative loss of ICC.56

PATIENT PERSPECTIVE

“Over the years I’ve seen a lot of doctors, and I’m
exhausted. I have many health issues, with type 1
diabetes being the longest at play. My first gastric
symptoms included bloating and nausea; I needed
answers and quick. So, I went to a doctor, who sent me
to another doctor ─ thankfully one who believed me
and recognized my symptoms ─ who made a diagnosis
then and there: DG.
Review

“When I first received my DG diagnosis about 15 years
ago, I was living in Canada and no tests were widely
available for confirmation. After moving to England in
2013, my symptoms became disabling and I underwent
some testing. A gastric emptying study came first.
Result? Radioactive egg sat immobile in my stomach
all day. I was told to return first thing the next morning
for yet another nuclear medicine scan. Shock etched
itself on the radiologist’s face. Nothing had moved.
Rotting food in your stomach for days? It’s no picnic
in the park.
“I tried many medications, including metoclopramide,
cisapride, domperidone, erythromycin, to name a few,
all to no avail. My surgeon thought my symptoms were
so severe that I needed to have a gastric pacemaker
implanted (given its trade name is Enterra, I
dubbed it ‘Terry’). In my case, I can only describe
the pacemaker in one word: disaster. The two years
following were lost to indescribable pain. I did not
get any benefit, and I lost weight and had back pain.
My view was that ‘Terry’ had to go. Now that ‘Terry’
has been removed, I don’t feel the added pain, but
the DG has not changed, and I still have to be very
careful about what and how I eat.
“I’m one of the ‘lucky’ ones. I’ve been heard; I’ve
been believed; I’ve been properly diagnosed. I have
also connected to online patient groups, such as the
Gastroparesis & Intestinal Failure Trust (GIFT),
which is a ‘for patients by patients’ nonprofit support
and research organization. I’ll be honest. This group
is both encouraging and terrifying: so many questions
answered; suggestions of what could help; acceptance;
people who understand. No doctor could ever portray
the brutalities of DG like other patients, as well as
the courage and strength it takes to live with it. We,
your patients, are people ─ broken, brave, resilient,
shattered, strong. Yes, I’ve seen a lot of doctors, and I
have hope. There is an urgent need for more research,
more awareness, more compassion, and I hope, in
time, the development of a cure.”

CONCLUSIONS

Although improvements in the understanding of the
pathophysiology of diabetic gastroparesis have been
made, to date there has been limited progress in the
development of new treatments that translate to
improved outcomes for patients. Given the burden
Review

of disease and the associated morbidity, DG remains
an area of significant unmet clinical need. Phase III
clinical trials of novel agents, such as the ghrelin
agonist relamorelin, are currently underway in patients
with DG and, if efficacy is demonstrated, will represent
welcome addition to the therapeutic armamentarium.

Patient-Friendly Recap
• Gastroparesis involves delayed emptying of the
stomach, which can lead to recurrent nausea,
bloating, and vomiting. Those living with
this condition are at risk for dehydration and
malnutrition.
• Gastroparesis in diabetics is common but often
underrecognized, particularly in primary care.
• While pharmacological, endoscopic, and
surgical approaches to treatment are available,
results vary by individual and gains are limited.
• A frank account as told by one patient with
diabetic gastroparesis exemplifies the
challenges faced in battling this disease.
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